Litigation Details for Novartis Pharmaceuticals Corporation v. Handa Neuroscience, LLC (D. Del. 2021)
✉ Email this page to a colleague
Novartis Pharmaceuticals Corporation v. Handa Neuroscience, LLC (D. Del. 2021)
| Docket | ⤷ Sign Up | Date Filed | 2021-05-04 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:1 Patent Infringement | Assigned To | Leonard Philip Stark |
| Jury Demand | Referred To | ||
| Patents | 10,543,179; 9,187,405 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Novartis Pharmaceuticals Corporation v. Handa Neuroscience, LLC
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Novartis Pharmaceuticals Corporation v. Handa Neuroscience, LLC (D. Del. 2021)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2022-02-28 | 47 | Opinion - Memorandum Opinion | and 10,543,179 (the" ' 179 patent"). (Id. ,r 1) Two days later, Plaintiff …enforce two patents covering GILENYA® : U. S. Patent Nos. 9,187,405 (the '"405 patent") and… In a patent infringement action, venue is governed solely and exclusively by the patent venue statute… of Novartis litigating these patents; especially the ' 405 patent in this district for years successfully…District of California, asserting the same two patents against the same four Defendants, purportedly | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
